Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H20F4N2O2 |
Molecular Weight | 408.3893 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC(=CC=C1)N(CC2=CC(F)=C(F)C(F)=C2)C(=O)O[C@H]3CN4CCC3CC4
InChI
InChIKey=UXZDMXYRRQJIBJ-IBGZPJMESA-N
InChI=1S/C21H20F4N2O2/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26/h1-3,8-10,14,19H,4-7,11-12H2/t19-/m0/s1
Molecular Formula | C21H20F4N2O2 |
Molecular Weight | 408.3893 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tarafenacin (also known as SVT-40776) was developed as muscarinic M3 receptor antagonist for the treatment of overactive bladder. The drug participated in phase II clinical trial in patients suffering from overactive bladder, where both dose levels of tarafenacin were well tolerated. However, information about the further development of tarafenacin is not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21524581 |
1.5 nM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01458197
Tarafenacin 0.2 mg and Tarafenacin 0.4 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:48:29 GMT 2023
by
admin
on
Sat Dec 16 15:48:29 GMT 2023
|
Record UNII |
LDV98UN52Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
25147683
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
DTXSID301319099
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1779046
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
C87644
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
300000037038
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
LDV98UN52Y
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
385367-47-5
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY | |||
|
9065
Created by
admin on Sat Dec 16 15:48:29 GMT 2023 , Edited by admin on Sat Dec 16 15:48:29 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|